Triple-negative breast cancer trials in Germany

In Germany 27 Also abroad 425

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in Germany
An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
Where
Munich
Age
18 years and over
People
20
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 · EU 2025-523824-39-01
Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Erlangen, Essen
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Berlin, Chemnitz, Duesseldorf, Erlangen, Essen, Freiburg Im Breisgau, Georgsmarienhuette, Hamburg, Hanover, Ludwigsburg, Luebeck, Magdeburg, Mainz, Moenchengladbach, Munich, Potsdam, Saarbruecken, Trier, Troisdorf, Tuebingen, Westerstede, Witten
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Augsburg, Berlin, Bielefeld, Bottrop, Braunschweig, Bremen, Cologne, Dortmund, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Gelsenkirchen, Georgsmarienhuette, Gera, Hamburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Langen (Hessen), Leipzig, Mannheim, Muehlhausen/thueringen, Muenster, Munich, Offenbach Am Main, Oldenburg, Paderborn, Potsdam, Ravensburg, Rostock, Schwerin, Stade, Stuttgart, Tuebingen, Ulm, Wiesbaden, Witten, Worms, Wuppertal
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Augsburg, Berlin, Braunschweig, Bremen, Dresden, Essen, Frankfurt Am Main, Freiburg Im Breisgau, Georgsmarienhuette, Gera, Hamburg, Koblenz, Mainz, Mannheim, Munich, Nuremberg, Ravensburg, Rostock, Worms
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
No phaseTaking people
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Where
Essen
Age
18 years to 75 years
People
60
Run by
Kliniken Essen-Mitte
See details and how to joinNCT07311083
Phase 1Not yet taking people in Germany
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Berlin, Düsseldorf, Erlangen, Essen, Leipzig, Saarbrücken
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Berlin, Duesseldorf, Erlangen, Hamburg, Koblenz, Muenster, Munich, Paderborn, Saarbruecken
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Essen
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Essen
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Augsburg, Berlin, Bonn, Dresden, Essen, Esslingen am Neckar, Frankfurt Am Main, Hanover, Heidelberg, Langen (Hessen), Luebeck, Munich, Ulm
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 3Not yet taking people in Germany
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Where
Aachen, Augsburg, Bad Nauheim, Bonn, Cologne, Cottbus, Dortmund, Eschweiler, Essen, Guetersloh, Hamburg, Hamm, Heilbronn, Hildesheim, Kassel, Moenchengladbach, Muenster, Munich, Regensburg, Rodewisch, Schwerte, Troisdorf, Weinheim, Witten, Wuerzburg
Age
18 years and over
People
765 worldwide
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT07178730 · EU 2024-516734-35-00
Phase 3Taking people
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Where
Ahlen, Augsburg, Baden-Baden, Berlin, Bielefeld, Boeblingen, Bremen, Bremerhaven, Chemnitz, Cologne, Dortmund, Duesseldorf, Eschweiler, Essen, Frankfurt am Main, Freiburg, Freiburg Im Breisgau, Gelsenkirchen, Georgsmarienhuette, Gröbenzell, Hamburg, Hamm, Heilbronn, Herne, Hildesheim, Kassel, Leipzig, Leverkusen, Moenchengladbach, Muenster, Munich, Münster, Potsdam, Rastatt, Saarbruecken, Schwelm, Schwerte, Sindelfingen, Sinsheim, Stendal, Trier, Troisdorf, Tuebingen, Ulm, Weinheim, Witten, Wuppertal
Age
18 years and over
People
348
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT06081244 · EU 2023-508787-29-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Cologne, Essen, München, Rostock
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Berlin
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Not yet taking people in Germany
First-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer
Where
Aachen, Duesseldorf
Age
18 years and over
People
18
Run by
Universitaetsklinikum Aachen AöR
See details and how to join2025-524027-49-00 · EU 2025-524027-49-00
Phase 1/2Taking people
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Where
Erlangen, Heidelberg, Tuebingen
Age
18 years and over
People
28
Run by
NEC Bio B.V
See details and how to joinNCT06631092 · EU 2024-512520-11-00
Phase 2Taking people
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Where
Berlin, Bielefeld, Bonn, Eschweiler, Essen, Frankfurt Am Main, Georgsmarienhuette, Goslar, Munich, Troisdorf, Tuebingen, Witten
Age
18 years to 64 years
People
140 worldwide
Run by
Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00
No phaseTaking people
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Where
Tübingen
Age
18 years and over
People
225
Run by
University Hospital Tuebingen
See details and how to joinNCT05914961
No phaseNot yet taking people in Germany
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
Where
Heidelberg
Age
18 years and over
People
600 worldwide
Run by
OncoHost Ltd.
See details and how to joinNCT07246759